Pro Medicus shares climb as FY25 results hit forecasts
Make us a preferred source
Make us a preferred source on Google
More news: Pro Medicus was the top performer on the ASX 200 in early trade after the medical imaging company reported a 39% lift in full-year net profit this morning.
Shares were up 6.4% to $316.26 at 10:50am AEST, having surged 124% over the last 12 months.
RBC Capital Markets analyst Garry Sherriff said the result was "broadly in line with consensus" with net cash of $174 million topping average forecasts of $152 million. He said the net cash position gives the company "ample opportunity to continue to expand organically and pursue potential M&A".
Sherriff also noted Pro Medicus' outlook "remains upbeat" with most of the contracts won in the second half of FY25 coming online in FY26.
Pro Medicus delivers 39% gain in full-year profit
The news: Healthcare imaging software developer Pro Medicus has posted a 39.2% increase in net profit for financial year 2025 and declared a higher final dividend when compared to the previous year after signing $520 million worth of new contracts.
The numbers: Pro Medicus' full-year net profit came in at $115.2 million, which is higher than the $82.8 million reported in the previous year. Revenue from ordinary activities came in at $213 million, 31.9% higher year on year than $161.5 million.
A final fully-franked dividend of 30 cents per share was declared, an increase compared to the 22 cents fully-franked final dividend declared for FY24.
The company’s cash and other financial assets were valued at $210.7 million by the end of June 2025, compared to $155.4 million 12 months earlier.
The market consensus estimate for net profit was $113.4 million, according to Visible Alpha, and for revenue was $213 million. The consensus was for a 55 cents dividend per share.
The context: Pro Medicus posted record half-year profit for 2025 and signed $520 million worth of new contracts and renewed $130 million in contract renewals.
Revenue in all key jurisdictions lifted throughout the year, namely in North America (+35.8%), Australia (+4.9%) and Germany (+8.6%).
What they said: "We now have around 10% of the total addressable market in the US which is material, but it also means there is plenty of scope for further growth," Pro Medicus CEO Sam Hupert said.
